Draft genome sequence data and comparative analysis of Erysipelothrix Rhusiopathiae vaccine strain VR-2
- PDF / 791,746 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 192 Views
GENOME REPORTS
Draft genome sequence data and comparative analysis of Erysipelothrix Rhusiopathiae vaccine strain VR‑2 Svetlana N. Kovalchuk1 · Anna V. Babii1 Received: 21 July 2020 / Accepted: 21 September 2020 / Published online: 29 September 2020 © King Abdulaziz City for Science and Technology 2020
Abstract Erysipelothrix rhusiopathiae VR-2 is a commercially available live attenuated vaccine strain widely used in Russia, Kazakhstan, and a number of European countries for immunization of pigs against swine erysipelas. The draft genome sequence of E. rhusiopathiae strain VR-2 reported in this paper is 1,704,727 bp in length, has CG content of 36.5%, and contains 1680 genes, including 51 tRNA, 3 rRNA, and 1408 protein-coding genes. Comparative sequence analysis between Fujisawa (serovar 1a), VR-2 and six other serovar N strains of E. rhusiopathiae revealed wide genetic variability of the chromosomal region essential for serovar-specific antigenicity and virulence of E. rhusiopathiae strains. We have performed a BLAST search and found 12 genomic loci potentially specific for the E. rhusiopathiae VR-2 strain. These data could be helpful for developing genetic assays for differentiation of field isolates and this live attenuated vaccine strain, which is especially important for epizootical monitoring of swine erysipelas in countries, where the live vaccine strain E. rhusiopathiae VR-2 is used for pig immunization, as well as for the design of recombinant vaccines against swine erysipelas. The genome of E. rhusiopathiae VR-2 has been submitted in GenBank under accession number RJTK00000000.1. Erysipelothrix rhusiopathiae is a gram-positive, non-sporeforming, rod-shaped bacterium that causes erysipeloid in humans and erysipelas in animals, including swine erysipelas (Wood, 2006). The clinical signs of swine erysipelas manifest as acute septicemia (acute phase of swine erysipelas), urticaria (subacute phase) and arthritis, lymphadenitis, and endocarditis (in the chronic stage of the disease). Due to the economic importance of swine erysipelas in the swine industry, an epizootic of E. rhusiopathiae is controlled by the administration of commercially available E. rhusiopathiae vaccines in many countries (Mansfield and Fox 2018). In Russia, Kazakhstan, and a number of European countries E. rhusiopathiae live attenuated vaccine strain Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13205-020-02451-7) contains supplementary material, which is available to authorized users. * Svetlana N. Kovalchuk [email protected] Anna V. Babii [email protected] 1
Federal Science Center for Animal Husbandry Named After Academy Member L.K. Ernst, Dubrovitsy 60, Podolsk Municipal District 142132, Moscow Region, Russian Federation
VR-2 is widely used for immunization of pigs against swine erysipelas. The E. rhusiopathiae VR-2 strain (serovar N) was isolated in 1931 in the Pasteur Institute in Bucharest from a pig that died from swine erysipelas. The attenuated E. rhusiopathia
Data Loading...
